Amundi Reduces Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Amundi cut its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 43.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,743 shares of the company’s stock after selling 116,594 shares during the period. Amundi’s holdings in BioNTech were worth $16,428,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. LRI Investments LLC increased its holdings in BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of BioNTech during the 1st quarter worth approximately $80,000. Allworth Financial LP increased its stake in shares of BioNTech by 1,176.8% during the 2nd quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock worth $129,000 after purchasing an additional 1,118 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $167,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $95.74 on Thursday. The company has a market cap of $21.56 billion, a P/E ratio of -36.40 and a beta of 1.30. The business has a fifty day simple moving average of $102.65 and a 200-day simple moving average of $105.09. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the previous year, the business posted $0.81 earnings per share. The firm’s quarterly revenue was up 22.0% on a year-over-year basis. Equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on BNTX shares. Jefferies Financial Group reiterated a “buy” rating and set a $151.00 target price on shares of BioNTech in a report on Wednesday, December 3rd. JPMorgan Chase & Co. reduced their price objective on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Bank of America decreased their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Morgan Stanley reissued an “overweight” rating and issued a $134.00 target price on shares of BioNTech in a research note on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average price target of $136.42.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.